GeneDx price target raised to $165 from $140 at BTIG

BTIG raised the firm’s price target on GeneDx (WGS) to $165 from $140 and keeps a Buy rating on the shares. The company delivered another strong quarter, posting best-in-class 65% Y/Y growth in its core exome/genome revenue, resulting in an 11% top line beat and a beat to the bottom line, and the management raised its 2025 guidance, the analyst tells investors in a research note. In order to capitalize on penetrating at least one large new market opportunity – the pediatrician market – GeneDx has initiated a step-up in hiring/spending, the firm added.